Sustainability Report for 2021
During 2021, we have taken important steps to create more value from our sustainability efforts by better articulating the health impact of our investment approach. As part of these efforts, we have also set out to fully integrate sustainability in our investment process and engagement with our portfolio companies. We hope you will enjoy reading more about our journey in Impilo’s Sustainability Report 2021.
Read the full report hereNews
Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions
The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.